Recombinant Mouse DR5 Protein (His Tag)
Beta LifeScience
SKU/CAT #: BLPSN-1658
Recombinant Mouse DR5 Protein (His Tag)
Beta LifeScience
SKU/CAT #: BLPSN-1658
Product Overview
| Tag | His |
| Host Species | Mouse |
| Accession | NP_064671.2 |
| Synonym | DR5, KILLER, Ly98, MK, TRAILR2, TRICK2A, TRICK2B, TRICKB |
| Background | Tumor necrosis factor receptor superfamily, member 1b, official symbol TNFRSF1B, also known as Death receptor 5, CD262, TNF-related apoptosis-inducing ligand receptor 2 (TRAIL R2), is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF1/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein. TRAIL R2/CD262/TNFRSF1B was purified independently as the only receptor for TRAIL detectable on the surface of two different human cell lines that undergo apoptosis upon stimulation with TRAIL. TRAIL R2/CD262/TNFRSF1B contains two extracellular cysteine-rich repeats, typical for TNF receptor (TNFR) family members, and a cytoplasmic death domain. TRAIL R2/CD262/TNFRSF1B mediates apoptosis via the intracellular adaptor molecule FADD/MORT1. TRAIL receptors can signal both death and gene transcription, functions reminiscent of those of TNFR1 and TRAMP, two other members of the death receptor family. Defects in TRAIL R2/CD262/TNFRSF1B may be a cause of head and neck squamous cell carcinomas (HNSCC) also known as squamous cell carcinoma of the head and neck.Immune CheckpointImmunotherapyCancer ImmunotherapyTargeted Therapy |
| Description | A DNA sequence encoding the extracellular domain of mouse TNFRSF10B (NP_064671.2) (Met 1-Ser 177) was expressed, with a C-terminal His tag. |
| Source | HEK293 |
| Predicted N Terminal | Asn 53 |
| AA Sequence | Met 1-Ser 177 |
| Molecular Weight | The secreted recombinant mouse TNFRSF10B consists of 136 a.a. and has a calculated molecular mass of 15 kDa. As a result of glycosylation, the apparent molecular mass of the recombinant protein is approximately 25-35 kDa in SDS-PAGE under reducing conditions. |
| Purity | >95% as determined by SDS-PAGE |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method |
| Bioactivity | 1. Immobilized mouse TNFRSF10B-His at 10 ug/ml (100 ul/well) can bind biotinylated human TNFSF10, The EC50 of biotinylated human TNFSF10 is 0.16-0.38 ug/ml.2. Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L-929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is typically 0.5-2 ug/mL in the presence of 20 ng/ml Recombinant Human TRAIL/TNFSF10. |
| Formulation | Lyophilized from sterile PBS, pH 7.4. |
| Stability | The recombinant proteins are stable for up to 1 year from date of receipt at -70°C. |
| Usage | For Research Use Only |
| Storage | Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
